Overview
- Oku Digital Health launched from Topcon Healthcare, connecting a network of 10,000+ point-of-care locations with pharmaceutical drug development.
- Its Harmony solution uses ophthalmic imaging and clinical data to identify treatment-naïve patients, support clinical trial recruitment, and generate longitudinal real-world evidence.
- The platform is designed to support drug development across ocular, cardiovascular, renal, metabolic, and neurodegenerative diseases.
The News
Oku Digital Health has launched a digital health platform designed to use routine eye-care data to accelerate pharmaceutical research and clinical development. Through its connected point-of-care network, Oku provides sponsors with access to longitudinal retinal imaging and linked clinical data that can help identify potential trial candidates, select sites, and generate real-world evidence.
Its Harmony solution uses multimodal AI to analyze OCT and fundus imaging alongside clinical data, identifying signals associated with disease during routine eye examinations. Oku also offers AI-assisted Reading Center Services that combine automated analysis with human expert review to support data integrity and clinical trial submissions.
Industry Perspective
Routine eye examinations provide a potentially valuable source of opportunistic disease screening and longitudinal health data. By connecting point-of-care imaging with clinical development workflows, Oku aims to address recruitment challenges, reduce screening inefficiencies, and expand the use of ophthalmic biomarkers beyond traditional eye diseases.
Strategic Impact
The launch positions Oku at the intersection of AI-enabled diagnostics, real-world data, and pharmaceutical clinical development. Its ability to connect treatment-naïve patients, verified site-level data, and longitudinal ocular evidence could help sponsors improve trial recruitment, optimize study design, and support evidence generation throughout the drug development lifecycle.
Source: Globenewswire
